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Green Biotechnology in Belgium 




Belgium has firmly established itself as an international red biotechnology 
- i.e. pharmaceutical and healthcare applications - country, with a world 
class biotechnology industry in the Flanders and Wallonia bioRegions. But 
what about green biotechnology? 
 
This contribution explores the long-standing evolution of the green 
biotechnology cluster in the bioRegion of Flanders (Belgium), in particular 




The global biotechnology economy is knowledge-based and a major engine 
for regional economic growth with clusters of biotechnology companies 
situated around major publicly-funded research universities and institutions. 
According to Pereira (2006), It is “a complex network of corporate players, 
dominated by large firms with strong marketing capabilities and start-up 
firms that focus on research and development”.  A large number of studies 
focus on red biotechnology, i.e. pharmaceutical and healthcare applications. 
 
Belgium has firmly established itself as an international red biotechnology 
- i.e. pharmaceutical and healthcare applications - country, with a world 
class biotechnology industry in the Flanders and Wallonia bioRegions. The 
bioRegions of Flanders and Wallonia host a number of global players in 
medical research and development.  Segers (2017) analyzed the interplay 
between new and innovative biotechnology firms, the influence of 
strategic alliances (interfirm partnerships) with large (global) 
pharmaceutical companies and the role that open innovation might play in 
the further reinforcement of these relationships within regional 
biotechnology clusters (bioRegions). 
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But what about green biotechnology ?   Green biotech refers to plant 
biotechnology or plant genetic engineering, agro-food biotech including 
renewable energy from agricultural resources stimulated by plant genome 
research.  According to Doranova (2016), many activities in agricultural 
biotechnology also have a strong relevance to industrial biotech and bio-
based economy. 
 
Mirroring the development in the medical (red) biotechnology industry, 
the plant biotechnology industry originated in the 1980s through the 
creation of new biotechnology firms focused on making plants resistant 
against diseases and drought (Knockaert et al, 2015).    
 
Plant science research opened up new possibilities through its convergence 
with traditional sciences, such as agronomics, and new fields of research, 
such as biosciences (OECD, 2009).   The focal areas of research and 
development being crop protection, genetic modification of crops, hybrid 
seed technology and other biotechnological innovations in agriculture.  
Corporate activity in agriculture was targeted principally on new plant 
variety development.   As Oakey et al. (1990) pointed out, the improve-
ments in the ability of scientists to regenerate whole plants from cultured 
cells, together with developments in plant genetic engineering, promised to 
reduce dramatically the time required to develop new plant varieties and so 
expand the scope of crop cultivation. 
 
This contribution explores the long-standing evolution of the green 
biotechnology cluster in the bioRegion of Flanders (Belgium), in particular 
in the Ghent innovation district. 
 
Clusters, bioRegions and Innovation Districts 
 
At the regional level, the successful establishment of an efficiently 
operating industry sector through value-added growth, competitive 
advantage and an increase in employment takes place within 
geographically localized networks – called clusters.   Cooke (2002) refers 
to it “as an instance of rather strong sectoral, regional innovation systems 
capabilities, though integrated also to global knowledge supply and 
markets”. 
 
A cluster is “a geographical concentration of actors in vertical and 
horizontal relationships, showing a clear tendency of cooperating and 
sharing their competencies, all involved in a localized infrastructure of 
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support” (Zechendorf, 2011).  They include government agencies, public 
organizations, higher education and research institutions, cooperating 
companies, suppliers and financial structures.   They compete and 
cooperate simultaneously within the same industry sector.  Geographical 
proximity provides a platform for strong cooperation and the flow of 
knowledge and expertise between research institutions, companies and 
policy makers. 
   
For the purpose of this study, a bioRegion is defined by the definition of 
the European Commission (PwC, 2011; Zechendorf, 2008; 2011): “Any 
geographically meaningful entity which can, but has not necessarily, to be 
a political or administrative entity for which the promotion of biotech 
and/or life sciences has been defined as a priority.  Such a bioRegion can, 
but need not, contain one or several bioclusters and biotech, bioscience, 
life sciences parks, which are supposed to interact in order to enhance their 
efficiency”.       
 
Katz and Wagner (2014) refer to the rise of Innovation Districts: a 
geographic area where anchor institutions and companies cluster and 
connect with small firms, start-ups, business incubators and accelerators. 
 
The Flanders Institute of Biotechnology 
 
From the beginning of the 1980s, there was a strong regional focus on 
programmes fostering network structures between science and industry. 
Regional policymakers in Flanders and Wallonia initiated successive 
regional technology policies. The basic purpose of these region-specific 
technology policies was to mobilize regional research and technology 
development resources in order to stimulate self-generating regional growth 
(Donckels and Segers, 1990). The emphasis was and still is on regional 
technology clustering, new technology based firm creation and on building 
international strategic alliances (interfirm technology partnerships).  
Networked research centers and interuniversity poles were created to 
provide a strategic orientation for research (OECD, 2006). 
 
Biotechnology in Belgium is closely linked to the chemicals industry. 
Regional policymakers in Flanders and Wallonia gave a priority status to 
biotechnology as one of the focal generic technologies.  To support this 
process, the private sector created a support network of high technology 
product groups (Flanders) and “pôles de compétitivité” (Wallonia).   
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In the Flanders bioRegion the FIB - Flanders Institute of Biotechnology 
(Vlaams Instituut voor Biotechnologie – VIB) was established.   FIB  
(VIB, 2013; 2014) is an regional government funded institution that 
focuses on translating basic scientific results into pharmaceutical, 
agricultural and industrial applications.  It was created in 1996 as a unique 
biotechnology research platform.  One of its key goals is technology 
transfer, i.e. to convert research results into commercial activities.  
 
The FIB (VIB) unites life sciences departments and research centers from 
the main Flemish universities (Ghent, Leuven, Antwerp, Brussels, 
Hasselt), research parks, bio-incubators and bio-accelerators, academic 
hospitals and clinical research organizations.  VIB has a substantial patent 
portfolio and takes part in a vast number of research and development and 
licensing agreements with small and large biotechnology and 
biopharmaceutical companies based in Flanders, Europe or the United 
States.  
 
The Flanders Institute of Biotechnology has a diverse portfolio of spin-offs 
in red or green biotechnology. Commercial exploitation of scientific results 
is achieved through the submission of patents.  As part of an open innovation 
strategy, the Flanders Institute of Biotechnology advances technology in the 
academic community and industry.  FIB (VIB) brings new findings to 
technology platforms that are the basis for the creation of innovative new 
biotechnology firms (Euris, 2012), as is shown in Fig. 1. 
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The regional systems of innovation led to the creation of world leading 
agrotech clusters with new companies emerging in the bioRegions of 
Flanders and Wallonia.   Similarly to the development in the medical 
biotechnology industry, many of these start-up companies originated from 
research at universities and research institutions.  These new biotech-
nology firms developed key agricultural biotechnology products, even 
though the large multinational –chemical – companies with global research 
and development and marketing networks eventually took the products to 
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The Ghent Innovation District 
 
Ghent in the Flanders bioRegion is home to one of the world’s largest 
concentrations of agro-biotechnology activities.  Biotech companies and 
the proximity of leading research centers like the Ghent Center for Plant 
Systems Biology create a unique synergy.   Plant biotechnology has grown 
over the years into a regional success story, driven by scientific excellence 
(i.e. entrepreneurial researchers) and high technology state of the art 
infrastructure.  
 
In 2012, DevGen – one of FIB (VIB)’s startups – was acquired by 
Syngenta, a major multinational agribusiness corporation.  With Bayer 
CropScience, BASF – via the acquisition of CropDesign, another FIB 
(VIB) spin-off – and Syngenta on location, three global players are now 
engaged in major R&D activities as part of the Ghent cluster (VIB, 2013; 
2014). 
 
One of the “star” plant biotechnology firms in Europe was Plant Genetic 
Systems (PGS).   PGS was established in 1982 as a spin-off of the research 
laboratories of professors Schell  and Van Montagu at the university of 
Ghent.  They mapped out a gene sequence and a genome sequence of a 
plant.    
 
Plant Genetic Systems was a joint venture between European investors and 
Advanced Genetic Systems (Oakland, California) (CHF, 2016).   The 
company is best known for its work in the development of insect-resistant 
transgenic plants.  In 1985, the company developed genetically engineered 
tobacco plants and in 1987 it produced plants genetically engineered for 
pest protection and tolerant of novel herbicides. 
 
In 1996 the company was acquired by AgrEvo. a large German agricultural 
chemicals manufacturing company.  In 2000, Aventis CropScience was 
formed through a merger of AgrEvo and Rhône-Poulenc Agro.  In 2002, 
Bayer CropScience was formed through Bayer's acquisition of the plant 
biotech branch Aventis CropScience.   Fuglie et al. (2011) mapped out the 
evolution of Plant Genetic Systems into Bayer CropScience.   This is 
shown in Fig. 2. 
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Fig. 2 – Fuglie et al. (2011), p. 33 - adapted 
 
Segers (1992; 1993; 1996) described the stepping stones in the startup, 
survival and growth  of Plant Genetic Systems.  Strategic partnerships 
(joint ventures, licensing agreements, co-marketing agreements) with 
leading seed companies and multinational chemical companies, mergers 
and direct acquisitions contributed significantly to the transition process of 
a technology driven new biotechnology firm into a market driven 
company.   For this purpose, strategic alliances were formed with 
Hilleshög AB (Sweden), Japan Tobacco, Clause (France) and Corvas 
international (United States). 
 
As is clear from Table 1, green biotechnology firms are well represented 
in the Flanders bioRegion – in particular in the Ghent innovation district – 
performing state of the art research in strategic alliances with global 
multinational agrobiotech companies such as Monsanto, Syngenta (now 
ChemChina), BASF and Bayer.   They mostly employ a “networked 
business model”, where companies establish collaborations of varying 
intensities with large international companies, in order to seek out 
synergies depending on their project and stage of development (Segers, 
2017b). 
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Corvas International  
(spinoff: Corvas NV) 
Centocor Inc. 
1996: acquired 































Hybrid rice Monsanto 
Sumitomo Chemical 
2012: delisting of 
DevGen > Syngenta 





















2006: acquired by 

































GlobalYeast Strain Excellulor Bioethanol production 
from waste 
Industrial Yeast Strains 
Bio-Based Chemicals 
 Performa Investimentos  
Table 1 - Green Biotech Firms (Ghent Innovation District)/extended Table 1 below 
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Open Innovation: good practice cases 
 
The international network structure of the green biotechnology industry in 
the Ghent innovation district is now exploring open innovation practices 
within public private partnerships. 
 
Chesbrough (2003) defines open innovation as “a paradigm that assumes 
that firms can and should use external ideas as well as internal ideas, and 
internal and external paths to market, as firms look to advance their 
technology”.   Chesbrough and Brunswicker (2013) differentiate between 
inbound open innovation (outside-in) where external knowledge flows 
inside the firm, and outbound open innovation (inside-out) where 
knowledge flows outside the firm.   According to Gay (2014), in the open 
innovation approach, there is a greater reliance on connection, 
collaboration and partnerships for innovative success. 
 
 
A number of good practices are emerging, such as: 
 
1. Flanders Biobased Valley and Bio Base Europe   
 
Flanders Biobased Valley (2016) is a public private partnership for the 
promotion of sustainable bio-energy (biochemicals – biomaterials) 
activities and economic development in the Ghent innovation district. 
 
Bio Base Europe is a strategic alliance between Ghent Bio-Energy Valley 
(Belgium) and Biopark Terneuzen (Netherlands).  It is the first open 
innovation and education center for the biobased economy in Europe.   
The Bio Base Europe Pilot Plant is open for business to European 
companies in the chemical, agro‐industrial, energy, food and other sectors.   
It is an open innovation cluster for the transition to a biobased economy.   
The cluster consists of a number of companies active in the field of 
bioenergy and biobased products in the port of Ghent, in cooperation with 
the university of Ghent. 
 
2. Open innovation at Bayer 
 
Bayer’s (2016) global open innovation approach offers different forms of 
cooperation (outside-in) along the value-chain, from traditional licensing 
agreements or strategic research alliances to public-private partnerships as 
well as its crowdsourcing program “Grants4Targets”.  The generation of 
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ideas in new crop protection is assisted through the Grants4Targets Crop 
Science program, giving young researchers quick access to funding, along 
with opportunities to engage in joint research. 
 
3. Avantium and BASF 
 
Synthetic biology, or synbio for short, is rapidly infiltrating multiple fields, 
from bioplastics to food technology and healthcare.  
 
Avantium created a new, high-quality plastic made from plant-based 
industrial sugars.  Avantium (2016) partners with BASF in a new joint 
venture “Synvina” for the production and marketing of furandicarboxylic 
acid (FDCA), which is produced from renewable resources, as well as the 
marketing of polyethylenefuranoate (PEF) based on the new chemical 





In this contribution, the Ghent green biotech innovation district in 
highlighted.    
 
It shows that triple helix (Business – Government – Academia) and public 
private frameworks provide good practices for new green biotechnology 
entrepreneurial ventures in conjunction with the strategic alliances with 
large global companies.   
 
Fruitful collaborations with top level university research institutions and 
cluster organizations such as the Flanders Institute of Biotechnology (VIB) 
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Table 1  -  Ghent Green Biotech Cluster + strategic alliances portfolio                            
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GlobalYeast Strain Excellulor Bioethanol production 
from waste 
Industrial Yeast Strains 
Bio-Based Chemicals 







+ 2016: Bayer acquisition of Monsanto  
 
Fig. 1: Fuglie et al. (2011), p. 33 – adapted 
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*IPO  Brussels EURONEXT stock exchange listing 
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